INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Tesaro, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
November 21, 2018 12:47 ET
|
Schall Law
LOS ANGELES, Nov. 21, 2018 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Tesaro, Inc. (“Tesaro” or...
TESARO Announces Second-Quarter 2018 Operating Results
August 02, 2018 16:05 ET
|
TESARO, Inc.
ZEJULA® Q2 net sales totaled $54 million compared to $26 million for Q2 2017QUADRA sNDA submission planned for Q4 2018PRIMA Phase 3 ZEJULA monotherapy trial in first-line ovarian cancer regardless of...
TESARO Announces Collaboration to Evaluate ZEJULA® in Combination With Anti-PD-L1 Cancer Immunotherapy and MEK Inhibitor in Platinum-Sensitive Ovarian Cancer
June 05, 2018 08:30 ET
|
TESARO, Inc.
WALTHAM, Mass., June 05, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that it has entered into a clinical collaboration with...
TESARO Announces Addition of ZEJULA to Cancer Drugs Fund in UK
June 01, 2018 03:00 ET
|
TESARO, Inc.
Inclusion in the Cancer Drugs Fund will give more women in England and Wales with recurrent, platinum-sensitive ovarian cancer access to ZEJULA via a managed access arrangementZEJULA was launched in...
TESARO and Medison Enter Into Exclusive Distribution Agreement to Commercialize ZEJULA® in Israel
April 11, 2018 08:30 ET
|
TESARO, Inc.
Agreement covers all indications for ZEJULA, excluding prostate cancer ZUG, Switzerland and PETACH TIKVA, Israel, April 11, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an...
TESARO Announces Availability of ZEJULA® (niraparib) for Women With Recurrent Ovarian Cancer in Germany
December 15, 2017 04:00 ET
|
TESARO, Inc.
ZEJULA is the first PARP inhibitor approved in Europe for women with recurrent ovarian cancer, without the need for BRCA testing and regardless of biomarker statusZEJULA is the only PARP inhibitor to...
TESARO Secures $500 Million Non-Dilutive Term Loan Financing
November 21, 2017 08:00 ET
|
TESARO, Inc.
WALTHAM, Mass., Nov. 21, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology focused biopharmaceutical company, announced today that it has entered into a definitive term loan agreement...
TESARO Announces European Commission Approval of ZEJULA® for Women With Recurrent Ovarian Cancer
November 20, 2017 07:00 ET
|
TESARO, Inc.
ZEJULA is the first PARP inhibitor approved in Europe for women with recurrent ovarian cancer, regardless of BRCA mutation or biomarker statusApproval supported by robust data from a randomized,...
TESARO Announces Third-Quarter 2017 Operating Results
November 07, 2017 16:05 ET
|
TESARO, Inc.
ZEJULA® was the most prescribed PARP inhibitor in U.S. with Q3 net sales of $39.4 millionPositive CHMP opinion issued for ZEJULA in E.U.; commercial launch anticipated to begin by year-endExpansion of...
TESARO Announces U.S. FDA Approval of VARUBI® IV for Delayed Nausea and Vomiting Associated With Cancer Chemotherapy
October 25, 2017 19:15 ET
|
TESARO, Inc.
VARUBI injectable emulsion features a ready-to-use, single-dose vial for intravenous administrationAvailability of new formulation offers healthcare providers the flexibility to choose oral or IV...